Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NEUPthis companyNeuphoria Therapeutics Inc.	$2.83	-1.43×	0×	16.36×	2,169.58×	104042.4%	43.5%	-835.5%	-1145.7%	-0.1%	-0.0%	-64303.7%	0×	2,171.68×	0×	27.85×	0.0%	1	-6.56	3	B
ALZNAlzamend Neuro Inc	$1.40	-0.43×	5.19×	0×	-0.36×	-113.5%	0.0%	0.0%	0.0%	-1196.4%	-1195.7%	-212.1%	0×	0.08×	1,324.5×	1.31×	0.0%	1	-12.93	2	C
APREAprea Therapeutics, Inc.	$0.53	-0.44×	0.45×	0×	0.72×	335.0%	0.0%	0.0%	0.0%	-101.3%	-100.5%	-231.2%	0×	1.16×	0×	5.63×	0.0%	3	-10.16	2	C+
BCDABioCardia, Inc.	$0.95	-1.02×	9.31×	0×	-0.82×	-76.9%	0.0%	0.0%	0.0%	-919.3%	-581.7%	-89.3%	0.59×	0.25×	0×	1.12×	0.0%	1	-51.25	2	C
BMRABiomerica, Inc.	$1.55	-1.82×	2.62×	1.54×	-1.62×	-596.1%	8.1%	-119.5%	-84.8%	-143.5%	-106.1%	-49.7%	0.91×	-0.22×	0×	1.62×	0.0%	1	-10.29	2	C
LUCYLucyd, Inc	$0.84	-0.52×	0.44×	1.49×	0.34×	-2524.3%	21.3%	-319.2%	-285.2%	-83.7%	-93.4%	-189.2%	0×	0.87×	0×	9.03×	0.0%	3	-1.19	2	C+
Peer median	—	-0.52×	2.62×	0×	-0.36×	-113.5%	0.0%	0.0%	0.0%	-143.5%	-106.1%	-189.2%	0×	0.25×	0×	1.62×	0.0%	1	-10.29	2	—